GATC Health Panel Spotlights Capital Efficiency and Risk Reduction at the AI Drug Discovery & Development Summit

Industry leaders showcased how advanced AI platforms are unlocking economic value and minimizing risk in clinical trial design and drug development at the Boston event.

GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, announced that Chief Business Officer V. Tyrone Lam and Head of AI Engineering Vaishnavi Narayan attended the AI Drug Discovery & Development Summit (AIDDD) in Boston, Massachusetts, from November 18-20, 2025. Lam participated in the expert panel session, “AI-Driven Clinical Development: From Protocol Design to Real-World Evidence,” which brought together industry leaders to discuss developments and capital efficiency in AI-powered clinical trials.

Lam’s panel addressed challenges faced by biotech companies due to limited funding for clinical trials, emphasizing how AI helped make capital deployment more efficient and accelerated progress toward successful outcomes. Lam explained that increased trial success and cash conservation have become essential for biotech survival. During the event, Lam highlighted several critical ways AI has reshaped clinical development—in smarter trial design, risk modeling, and patient selection. GATC Health’s Derisq™ AI Report was presented as pivotal for delivering objective, AI-powered insights that help biotech leaders and investors prioritize assets and predict outcomes—all before committing capital or entering the clinic.

“Today, most biotech companies are struggling with a fundamental question: how do we get our drugs through clinical trials when capital is scarce?” noted Lam. “AI isn’t just about making trials faster—it’s about making capital more efficient, reducing risk, and ultimately making biotech companies more fundable. If a company isn’t funded, clinical trials can’t start. That’s the economic reality we need to address.” 

The panel also featured GATC Health’s recent successes, including partnerships that validated its AI’s reliability for clinical trial risk prediction, achieving 91% specificity and 86% sensitivity, as confirmed by the University of California, Irvine. The company’s work with Lloyd’s of London on AI-backed clinical trial insurance was referenced as a groundbreaking example. Lam discussed ongoing industry barriers such as regulatory resistance to rapid AI adoption and institutional inertia, advocating for data-driven approaches to encourage further investment. Looking ahead, Lam projected that AI will continue to drive investment and expand therapeutic pipelines, fundamentally transforming how therapies reach patients. 

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.